Revised forecast
Fiscal year ending December 2026 · Second quarter (interim period)Previous forecast published 13 February 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Net sales fell below forecast because revenue recognition was deferred, among other reasons, due to circumstances involving business partners and other factors in the regenerative medicine CDMO business of the regenerative medicine support business. Meanwhile, profit exceeded forecast because, in addition to company-wide efforts to reduce expenses, the incurrence of certain costs was deferred until the third quarter or later, among other reasons.
| Item | Details |
|---|---|
| Net Sales | ¥32 million → ¥20 million（-37.5%） |
| Operating profit | ¥-580 million → ¥-570 million |
| Ordinary income | ¥-590 million → ¥-576 million |
| Profit attributable to owners of the parent | ¥-660 million → ¥-610 million |
| Net income per share | ¥-16.94 → ¥-15.93 |
| Fiscal Period Covered | Fiscal year ending December 2026 |
| Period Covered | Second quarter (interim period) |
| Publication date of previous forecast | 13 February 2026 |
| Previous-period results | Net sales of ¥36 million, operating loss of ¥623 million, ordinary loss of ¥623 million, interim net loss of ¥651 million, and interim net loss per share of ¥18.78 |
| Reason for the revision | Net sales fell below forecast because revenue recognition was deferred, among other reasons, due to circumstances involving business partners and other factors in the regenerative medicine CDMO business of the regenerative medicine support business. Meanwhile, profit exceeded forecast because, in addition to company-wide efforts to reduce expenses, the incurrence of certain costs was deferred until the third quarter or later, among other reasons. |
Items this document does not state (3)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Net sales fell below forecast because revenue recognition was deferred in the regenerative medicine CDMO business of the regenerative medicine support business due to circumstances involving business partners and other factors. Profit exceeded forecast because, in addition to company-wide efforts to reduce expenses, the incurrence of certain costs was deferred until the third quarter or later.